RUMORED BUZZ ON ABBV-744 FOR SMALL CELL LUNG CANCER RESEARCH

In Segment C, individuals will receive ABBV-744 and oral navitoclax. In Section D, contributors will receive ABBV-744 and ruxolitinib. Participants will obtain treatment right until ailment progression or the individuals are not able to tolerate the study drugs.- "Our study exposed the vital part in the KLF16/MYC regulatory axis in modulating tumor